FINAL

May 25, 2021

Clarification Memo 2

Protocol

Version 1.0

HVTN 136/HPTN 092

A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous or subcutaneous infusions in healthy, HIV-uninfected adult participants

DAIDS-ES ID 38634

[BB IND #146153—HELD BY DAIDS]

HIV Vaccine Trials Network (HVTN) Clinical Research Site (CRS) filing instructions

Please distribute this clarification memo to all appropriate staff members, and file with your protocol documents. Consult your local Institutional Review Board (IRB)/Ethics Committee (EC) regarding submission requirements for clarification memos.

List of changes

The changes described herein will be incorporated in the next version of Protocol HVTN 136/HPTN 092 if it undergoes full protocol amendment at a later time. New text is shown as **bold underlined**. Deleted text is shown with ~~strikethrough~~.

Item 1 Clarified in Sections 8, *Study product preparation and administration*: administration of subcutaneous infusion of the study products

To avoid errors in subcutaneous administration of the study products, we have revised Sections 8.4.2 and 8.4.4 to ensure that pharmacists refer to the HVTN 136/HPTN092 Study Specific Procedures (SSP).

A Section 8.4.2, PGT121.414.LS (Subcutaneous Infusion)

Revised:

PGT121.414.LS will be administered via SC infusion at a rate of 15 mL/hr. A suitable needle for SC infusion should be affixed to the prepared product prior to administration. **Refer to the HVTN 136/HPTN 092 SSP for further information on SC administration.**

B Section 8.4.4, VR07-523LS (Subcutaneous Infusion)

Revised:

VRC07-523LS will be administered via subcutaneous infusion at a rate of 15 mL/hr. A needle suitable for SC infusion should be affixed to the prepared product prior to administration. **Refer to the HVTN 136/HPTN 092 SSP for further information on SC administration.**

Protocol modification history

Protocol modifications are made to HVTN protocols via clarification memos, letters of amendment, or full protocol amendments. HVTN protocols are modified and distributed according to the standard HVTN procedures as described in the HVTN Manual of Operations (MOP).

The version history of, and modifications to, Protocol HVTN 136/HPTN 092 are described below.

Date: May 25, 2021

Protocol version: Version 1.0
Protocol modification: Clarification Memo 2

Item 1 Clarified in Sections 8, *Study product preparation and administration*: administration of subcutaneous infusion of the study products

Date: September 18, 2020

Protocol version: Version 1.0
Protocol modification: Letter of Amendment 1

Item 1 Updated with changes described in Protocol Version 1, Clarification Memo 1, dated September 3, 2020

Item 2 Added in Section 9.3, *Enrollment and study product administration*, Section 9.4, *Follow-up visits,* Section 15, *Acronym and abbreviations,* and Appendices J– M, *Laboratory Procedures*: ALT, AST, alkaline phosphatase and creatinine in the chemistry panel

Item 3 Removed from Section 1, *Overview* and Appendices J-M, *Laboratory procedures:* Fred Hutch/University of Washington (Seattle, Washington, USA)

Item 4 Revised in Appendices S-V, *Visit Windows*: lower and upper allowable windows from visit 9.0 onwards

Item 5 Updated in Section 1.1, *Protocol Team*: Membership

Date: September 03, 2020

Protocol version: Version 1.0
Protocol modification: Clarification Memo 1

Item 1 Added IND number to the cover page

Item 2 Clarified throughout the protocol (in accordance with COVID-19 precautions): “Clinic Visits”

Date: October 8, 2019

Protocol version: 1.0

Original protocol